Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 187.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,126 shares of the company's stock after acquiring an additional 32,015 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.09% of PROCEPT BioRobotics worth $3,956,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Naviter Wealth LLC lifted its position in shares of PROCEPT BioRobotics by 6.0% in the 4th quarter. Naviter Wealth LLC now owns 3,089 shares of the company's stock worth $249,000 after purchasing an additional 176 shares during the period. Amundi lifted its position in shares of PROCEPT BioRobotics by 0.9% in the 4th quarter. Amundi now owns 20,143 shares of the company's stock worth $1,742,000 after purchasing an additional 183 shares during the period. Arizona State Retirement System lifted its position in shares of PROCEPT BioRobotics by 1.5% in the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock worth $1,150,000 after purchasing an additional 218 shares during the period. KRS Capital Management LLC lifted its position in shares of PROCEPT BioRobotics by 0.5% in the 4th quarter. KRS Capital Management LLC now owns 46,455 shares of the company's stock worth $3,741,000 after purchasing an additional 225 shares during the period. Finally, KBC Group NV lifted its position in shares of PROCEPT BioRobotics by 32.6% in the 3rd quarter. KBC Group NV now owns 1,531 shares of the company's stock worth $123,000 after purchasing an additional 376 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.
PROCEPT BioRobotics Stock Down 4.0 %
PRCT traded down $2.38 during trading on Tuesday, hitting $56.66. 473,663 shares of the company's stock were exchanged, compared to its average volume of 722,315. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The business's 50 day moving average is $70.07 and its two-hundred day moving average is $79.05. PROCEPT BioRobotics Co. has a fifty-two week low of $45.56 and a fifty-two week high of $103.81. The stock has a market cap of $3.11 billion, a P/E ratio of -29.13 and a beta of 1.05.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. As a group, equities analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.
Analysts Set New Price Targets
PRCT has been the topic of a number of recent analyst reports. Truist Financial restated a "buy" rating and issued a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Morgan Stanley dropped their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company reiterated an "overweight" rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and a consensus target price of $94.29.
Get Our Latest Stock Report on PROCEPT BioRobotics
PROCEPT BioRobotics Company Profile
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Further Reading
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
